{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T15:14:17Z","timestamp":1762787657974,"version":"build-2065373602"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-22920-4","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T15:09:21Z","timestamp":1762787361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ATF6 and pS6K as prognostic biomarkers in newly diagnosed diffuse large B-cell lymphoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Shuang","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"12","key":"22920_CR1","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1200\/JCO.20.01366","volume":"39","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski, G. S. et al. ROBUST: A phase III study of Lenalidomide Plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-Cell lymphoma. J. Clin. Oncol. 39(12), 1317\u20131328 (2021).","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"22920_CR2","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump, M. et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16), 1800\u20131808 (2017).","journal-title":"Blood"},{"issue":"5","key":"22920_CR3","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/bjh.15412","volume":"182","author":"C Gisselbrecht","year":"2018","unstructured":"Gisselbrecht, C. & Van Den Neste, E. How I manage patients with relapsed\/refractory diffuse large B cell lymphoma. Br. J. Haematol. 182(5), 633\u2013643 (2018).","journal-title":"Br. J. Haematol."},{"issue":"6","key":"22920_CR4","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi, P. F. et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 22(6), 790\u2013800 (2021).","journal-title":"Lancet Oncol."},{"issue":"12","key":"22920_CR5","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1002\/bit.23282","volume":"108","author":"A Chakrabarti","year":"2011","unstructured":"Chakrabarti, A., Chen, A. W. & Varner, J. D. A review of the mammalian unfolded protein response. Biotechnol. Bioeng. 108(12), 2777\u20132793 (2011).","journal-title":"Biotechnol. Bioeng."},{"issue":"30","key":"22920_CR6","doi-asserted-by":"publisher","first-page":"10519","DOI":"10.1073\/pnas.0800939105","volume":"105","author":"DM Schewe","year":"2008","unstructured":"Schewe, D. M. & Aguirre-Ghiso, J. A. ATF6\u03b1-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo. Proc. Natl. Acad. Sci. 105(30), 10519\u201310524 (2008).","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"8","key":"22920_CR7","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1002\/tox.23814","volume":"38","author":"B Li","year":"2023","unstructured":"Li, B. et al. Hydroquinone-induced endoplasmic reticulum stress affects TK6 cell autophagy and apoptosis via ATF6-mTOR. Environ. Toxicol. 38(8), 1874\u20131890 (2023).","journal-title":"Environ. Toxicol."},{"issue":"1","key":"22920_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1172\/JCI73939","volume":"125","author":"YC Kim","year":"2015","unstructured":"Kim, Y. C. & Guan, K.-L. mTOR: A pharmacologic target for autophagy regulation. J. Clin. Investig. 125(1), 25\u201332 (2015).","journal-title":"J. Clin. Investig."},{"issue":"2","key":"22920_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/sj.cdd.4400978","volume":"9","author":"M Castedo","year":"2002","unstructured":"Castedo, M., Ferri, K. F. & Kroemer, G. Mammalian target of rapamycin (mTOR): Pro- and anti-apoptotic. Cell Death Differ. 9(2), 99\u2013100 (2002).","journal-title":"Cell Death Differ."},{"issue":"1","key":"22920_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1182\/blood-2018-08-872465","volume":"133","author":"K Bojarczuk","year":"2019","unstructured":"Bojarczuk, K. et al. Targeted inhibition of PI3K\u03b1\/\u03b4 is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood 133(1), 70\u201380 (2019).","journal-title":"Blood"},{"issue":"1","key":"22920_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41408-024-01085-9","volume":"14","author":"P Berning","year":"2024","unstructured":"Berning, P. et al. Hematopoietic stem cell transplantation for DLBCL: a report from the European society for blood and marrow transplantation on more than 40,000 patients over 32 years. Blood Cancer J 14(1), 106 (2024).","journal-title":"Blood Cancer J"},{"issue":"5","key":"22920_CR12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1089\/hum.2017.254","volume":"29","author":"U K\u00f6hl","year":"2018","unstructured":"K\u00f6hl, U., Arsenieva, S., Holzinger, A. & Abken, H. CAR T cells in trials: Recent achievements and challenges that remain in the production of modified T cells for clinical applications. Hum. Gene Ther. 29(5), 559\u2013568 (2018).","journal-title":"Hum. Gene Ther."},{"issue":"10","key":"22920_CR13","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella, M. et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat. Med. 24(10), 1499\u20131503 (2018).","journal-title":"Nat. Med."},{"issue":"3","key":"22920_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil, S., Duchateau, P., Grupp, S. A., Mufti, G. & Poirot, L. \u2018Off-the-shelf\u2019 allogeneic CAR T cells: Development and challenges. Nat. Rev. Drug Discovery 19(3), 185\u2013199 (2020).","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"5","key":"22920_CR15","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1053\/j.gastro.2018.07.028","volume":"155","author":"OI Coleman","year":"2018","unstructured":"Coleman, O. I. et al. Activated ATF6 induces intestinal dysbiosis and innate immune response to promote colorectal tumorigenesis. Gastroenterology 155(5), 1539-1552.e1512 (2018).","journal-title":"Gastroenterology"},{"key":"22920_CR16","doi-asserted-by":"publisher","first-page":"148436","DOI":"10.1016\/j.gene.2024.148436","volume":"915","author":"Y Wu","year":"2024","unstructured":"Wu, Y. et al. Identification of activating transcription factor 6 (ATF6) as a novel prognostic biomarker and potential target in oral squamous cell carcinoma. Gene 915, 148436 (2024).","journal-title":"Gene"},{"issue":"1","key":"22920_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12964-021-00810-2","volume":"20","author":"Y Yuan","year":"2022","unstructured":"Yuan, Y. et al. Endoplasmic reticulum stress promotes the release of exosomal PD-L1 from head and neck cancer cells and facilitates M2 macrophage polarization. Cell Commun. Signal. 20(1), 12 (2022).","journal-title":"Cell Commun. Signal."},{"issue":"12","key":"22920_CR18","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1016\/j.asjsur.2022.06.057","volume":"45","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q., Zhu, X. D., Sun, Q. N. & Wang, D. The UPR signaling molecule ATF6 is a poor prognostic marker in gastric cancer. Asian J. Surg. 45(12), 2836\u20132837 (2022).","journal-title":"Asian J. Surg."},{"issue":"20","key":"22920_CR19","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow, S. H. et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood 127(20), 2375\u20132390 (2016).","journal-title":"Blood"},{"issue":"1","key":"22920_CR20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/ng0993-66","volume":"5","author":"J-P Kerckaert","year":"1993","unstructured":"Kerckaert, J.-P. et al. LAZ3, a novel zinc\u2013finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas. Nat. Genet. 5(1), 66\u201370 (1993).","journal-title":"Nat. Genet."},{"issue":"8","key":"22920_CR21","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.4049\/jimmunol.1701321","volume":"200","author":"AL Raybuck","year":"2018","unstructured":"Raybuck, A. L. et al. B cell-intrinsic mTORC1 promotes germinal center-defining transcription factor gene expression, somatic hypermutation, and memory B cell generation in humoral immunity. J. Immunol. 200(8), 2627\u20132639 (2018).","journal-title":"J. Immunol."},{"issue":"9","key":"22920_CR22","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/onc.2014.61","volume":"34","author":"SR Walker","year":"2014","unstructured":"Walker, S. R. et al. The transcriptional modulator BCL6 as a molecular target for breast cancer therapy. Oncogene 34(9), 1073\u20131082 (2014).","journal-title":"Oncogene"},{"issue":"7448","key":"22920_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature12122","volume":"497","author":"H Yang","year":"2013","unstructured":"Yang, H. et al. mTOR kinase structure, mechanism and regulation. Nature 497(7448), 217\u2013223 (2013).","journal-title":"Nature"},{"issue":"11","key":"22920_CR24","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.2174\/1871520619666190416110851","volume":"19","author":"X Shao","year":"2019","unstructured":"Shao, X. et al. Prognosis, significance and positive correlation of Rab1A and p-S6K\/Gli1 expression in gastric cancer. Anticancer Agents Med. Chem. 19(11), 1359\u20131367 (2019).","journal-title":"Anticancer Agents Med. Chem."},{"issue":"4","key":"22920_CR25","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1016\/j.bbrc.2018.08.124","volume":"503","author":"X Wang","year":"2018","unstructured":"Wang, X., Yao, Y. & Zhu, X. The influence of aberrant expression of GLI1\/p-S6K on colorectal cancer. Biochem. Biophys. Res. Commun. 503(4), 3198\u20133204 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"22920_CR26","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.ygyno.2013.06.004","volume":"130","author":"Y Zhao","year":"2013","unstructured":"Zhao, Y. et al. The role of RhoC in ovarian epithelial carcinoma: A marker for carcinogenesis, progression, prognosis, and target therapy. Gynecol. Oncol. 130(3), 570\u2013578 (2013).","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"22920_CR27","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1158\/1078-0432.CCR-08-1543","volume":"15","author":"MY Zhao","year":"2009","unstructured":"Zhao, M. Y. et al. Phospho-p70S6K\/p85S6K and cdc2\/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy. Clin. Cancer Res. 15(5), 1708\u20131720 (2009).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"22920_CR28","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/1471-2407-13-250","volume":"13","author":"\u00c1 M\u00e1rk","year":"2013","unstructured":"M\u00e1rk, \u00c1. et al. Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease \u2013 a combined tissue microarray, in vitro and in vivo study. BMC Cancer 13(1), 250 (2013).","journal-title":"BMC Cancer"},{"issue":"1","key":"22920_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41420-022-01085-3","volume":"8","author":"R Benedetti","year":"2022","unstructured":"Benedetti, R. et al. ATF6 prevents DNA damage and cell death in colon cancer cells undergoing ER stress. Cell Death Discov. 8(1), 295 (2022).","journal-title":"Cell Death Discov."},{"issue":"5","key":"22920_CR30","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1016\/j.ajpath.2011.07.031","volume":"179","author":"A Mozos","year":"2011","unstructured":"Mozos, A. et al. The expression of the endoplasmic reticulum stress sensor BiP\/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large B-cell lymphoma. Am. J. Pathol. 179(5), 2601\u20132610 (2011).","journal-title":"Am. J. Pathol."},{"issue":"1","key":"22920_CR31","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s12672-025-02264-1","volume":"16","author":"S Su","year":"2025","unstructured":"Su, S. et al. ATF6 activation promotes tumorigenesis and drug resistance in diffuse large B-cell lymphoma (DLBCL) by regulating the mTOR\/S6K signaling pathway. Discover Oncol. 16(1), 499 (2025).","journal-title":"Discover Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22920-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22920-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22920-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T15:09:21Z","timestamp":1762787361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22920-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22920"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-22920-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"15 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All research was performed in accordance with relevant regulations. Each human sample was obtained with informed consent in strict compliance to the Declaration of Helsinki. This study was approved by the Fourth Hospital of Hebei Medical University and the Ethics Committee (Approval No. 2024KS191). The need for informed consent to participate was waived by the Fourth Hospital of Hebei Medical University and the Ethics Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"39326"}}